GMED vs MRNA
Globus Medical vs Moderna — AI-powered side-by-side comparison
GMED
Globus Medical
69
Buy
VS
| Metric | GMED | MRNA |
|---|
| AI Score |
69
|
61
|
| Price |
$83.02
|
$158.81
|
| P/E Ratio |
21.18×
|
-17.40×
|
| ROE |
11.8%
|
-32.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
-12.6%
|
| Debt / Equity |
0.02×
|
0.19×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
46.8
|
68.6
|
| Beta |
0.954
|
0.899
|
| Expected Upside |
+0.2%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus MRNA.
GMED leads by 8 points.
GMED scores 69/100 (Buy) versus MRNA at 61/100 (Buy).
GMED Committee View
100% agreement
6 analysts
The primary driver is eps growing 50.9% yoy. The main limiting factor is sector concentration is already high (hhi 3068.56). The committee is constructive but not yet at full conviction.
Bull Case
- EPS growing 50.9% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
MRNA Committee View
67% agreement
6 analysts
The primary driver is price structure making higher highs and higher lows. The main limiting factor is bollinger bandwidth of 194.9% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.3x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -39.2% -- cheap may mean cheap for a reason — Value
- Revenue declining -27.6% YoY -- this is not a growth story right now — Growth
- Weekly RSI at 82 -- overbought on the larger timeframe too — Technical